Antimicrobial activity of lomefloxacin (NY-198, SC 47111) against bacterial strains from Venezuela.
Lomefloxacin (SC 47111, NY-198) is a recently developed difluorinated quinolone that has been reported to be active against a broad range of both gram-positive and gram-negative pathogens in a number of laboratories around the world. Our laboratory tested the in vitro activity of 451 recent bacterial isolates compared to that of cephradine and gentamicin to define the in vitro spectrum of activity of this compound versus bacterial isolates from Venezuela. Lomefloxacin showed excellent in vitro activity versus Enterobacteriaceae with all isolates inhibited at a concentration of less than or equal to 2 mcg/ml. Lomefloxacin also had significant activity versus the aerobic gram-negative rods tested; the MIC90 for Pseudomonas aeruginosa being 4 mcg/ml. The activity of lomefloxacin versus gram-positive isolates was comparable to that of the gram-negative organisms. The MIC90 for S. aureus, S. epidermidis, and Group D Streptococcus were 1, 0.5 and 4 mcg/ml, respectively. The results of this study confirm the broad spectrum in vitro activity of lomefloxacin seen in earlier studies. Lomefloxacin appears to be active versus a wide variety of both gram-negative and gram-positive isolates including those resistant to cephradine and gentamicin. The excellent in vitro activity of lomefloxacin seen in this study shows that this compound could be a useful addition to currently available antimicrobial agents.